AZN Financials

Income Statement
MetricQ2 2016Q1 2016Q4 2015Q3 2015Q2 2015
Revenue
5.6B
-8.4%
6.1B
-4.4%
6.4B
+7.6%
5.9B
-5.7%
6.3B
Cost of Revenue
1.2B
+6.8%
1.1B
-21.1%
1.4B
+22.1%
1.1B
-2.7%
1.2B
Gross Profit
4.5B
-11.6%
5.0B
+0.1%
5.0B
+4.3%
4.8B
-6.4%
5.2B
Operating Expenses
4.1B
+3.8%
4.0B
+1.4%
3.9B
+7.9%
3.7B
-13.7%
4.2B
R&D
1.5B
-1.0%
1.5B
-15.2%
1.7B
+22.2%
1.4B
-2.5%
1.5B
SG&A
3.1B
+18.7%
2.6B
-3.6%
2.7B
-0.4%
2.7B
-9.7%
3.0B
Operating Income
303.0M
-70.8%
1.0B
-4.6%
1.1B
-7.0%
1.2B
+26.8%
923.0M
EBITDA
890.0M
-44.6%
1.6B
+47.7%
1.1B
-37.5%
1.7B
+6.2%
1.6B
Net Income
-31000000
-105.0%
625.0M
-22.6%
808.0M
+4.9%
770.0M
+10.6%
696.0M
EPS (Basic)
$0.00
-100.0%
$0.51
-19.0%
$0.63
+3.3%
$0.61
+10.9%
$0.55
EPS (Diluted)
$0.00
-100.0%
$0.51
-20.3%
$0.64
+6.7%
$0.60
+9.1%
$0.55
Shares (Diluted)
1.3B
+0.0%
1.3B
+0.0%
1.3B
+0.0%
1.3B
+0.0%
1.3B
AstraZeneca (AZN) โ€” Financials